Skip to main content
. 2012 Oct;14(10):926–942. doi: 10.1593/neo.12956

Figure 3.

Figure 3

Sensitivity of HCC1806-RR to various chemotherapeutics. MDA-MB-231 and HCC1806-RR lines were assessed for sensitivity to the following chemotherapeutic drugs: (A) nab-paclitaxel, (B) paclitaxel, (C) perifosine, (D) doxorubicin, (E) cisplatin, and (F) erlotinib. Each point represents the average percent of control ± SD derived from two independent experiments performed in duplicates.